Mingwei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingwei Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Junxuan Yi
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, China
2 shared publications - Shunzi Jin
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China
2 shared publications - Duo Yu
The Second Hospital of Jilin University
1 shared publication - Hanqi Zhang
Department of Radiotherapy, China-Japan Union Hospital of Jilin University, Changchun 130033, China
1 shared publication Hengqi Deng
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University
1 shared publication- Wei Kong
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 2001744
Post-translational modification networks in radiation-induced DNA damage repair: from mechanistic crosstalk to radiosensitization strategies
Radiotherapy (RT) is a cornerstone of cancer treatment, but intrinsic and acquired radioresistance remain major barriers to the therapeutic efficacy of RT. The capacity of tumor cells to repair radiation-induced DNA damage is a major determinant of treatment response. Post-translational modifications (PTMs) constitute a dynamic regulatory layer of the DNA damage response, influencing damage sensing, chromatin remodeling, repair-factor stability and recruitment, and repair pathway choice. This review examines how interacting PTMs regulate key repair nodes in homologous recombination (HR), canonical non-homologous end joining (c-NHEJ), alternative end joining (alt-EJ), base excision repair/single-strand break repair (BER/SSBR), and the Fanconi anemia (FA) pathway, with particular emphasis on multilayered PTM regulation of individual repair proteins and PTM crosstalk between different repair factors. We further compare PTM regulation of shared repair nodes in tumor and normal cells or tissues and discuss how differential dependence on common repair programs may influence therapeutic selectivity. Finally, PTM-targeted radiosensitization is evaluated in the context of the tumor–normal therapeutic window, with explicit distinction between active normal-tissue protection, preserved normal-tissue tolerance, and treatment-associated toxicity. Collectively, current evidence suggests the possibility of preferentially disrupting tumor DNA repair while limiting normal-tissue injury in selected settings.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 2001744
Open AccessPost-translational modification networks in radiation-induced DNA damage repair: from mechanistic crosstalk to radiosensitization strategies
Radiotherapy (RT) is a cornerstone of cancer treatment, but intrinsic and acquired radioresistance remain major barriers to the therapeutic efficacy of RT. The capacity of tumor cells to repair radiation-induced DNA damage is a major determinant of treatment response. Post-translational modifications (PTMs) constitute a dynamic regulatory layer of the DNA damage response, influencing damage sensing, chromatin remodeling, repair-factor stability and recruitment, and repair pathway choice. This review examines how interacting PTMs regulate key repair nodes in homologous recombination (HR), canonical non-homologous end joining (c-NHEJ), alternative end joining (alt-EJ), base excision repair/single-strand break repair (BER/SSBR), and the Fanconi anemia (FA) pathway, with particular emphasis on multilayered PTM regulation of individual repair proteins and PTM crosstalk between different repair factors. We further compare PTM regulation of shared repair nodes in tumor and normal cells or tissues and discuss how differential dependence on common repair programs may influence therapeutic selectivity. Finally, PTM-targeted radiosensitization is evaluated in the context of the tumor–normal therapeutic window, with explicit distinction between active normal-tissue protection, preserved normal-tissue tolerance, and treatment-associated toxicity. Collectively, current evidence suggests the possibility of preferentially disrupting tumor DNA repair while limiting normal-tissue injury in selected settings.
- Open Access
Reprogramming Fibrosis: How Protein PTMs Reshape the IPF Proteome
Idiopathic pulmonary fibrosis (IPF) is a fatal and progressive lung disorder. Its pathological process involves persistent epithelial damage, ongoing inflammation, and dysregulated tissue repair. Currently, there are no effective treatment methods to improve patient survival. However, post-translational modifications (PTMs) have gradually garnered widespread attention. They are the processes by which various chemical groups are added to or removed from proteins’ amino acid side chains or the N- or C-terminal ends of the polypeptide chain following synthesis. Additionally, they can regulate the energy supply of cells, regulate the cell cycle, and affect important signaling pathways such as TGF-β. This review systematically summarizes different categories of PTMs, organizes the PTMs involved in various injury stages of IPF, outlines the roles of different cells throughout the process, and analyzes future clinical diagnosis and treatment strategies as well as intervention targets for IPF, providing guiding significance for the systematic intervention of IPF in the future.
Open AccessReprogramming Fibrosis: How Protein PTMs Reshape the IPF Proteome
Idiopathic pulmonary fibrosis (IPF) is a fatal and progressive lung disorder. Its pathological process involves persistent epithelial damage, ongoing inflammation, and dysregulated tissue repair. Currently, there are no effective treatment methods to improve patient survival. However, post-translational modifications (PTMs) have gradually garnered widespread attention. They are the processes by which various chemical groups are added to or removed from proteins’ amino acid side chains or the N- or C-terminal ends of the polypeptide chain following synthesis. Additionally, they can regulate the energy supply of cells, regulate the cell cycle, and affect important signaling pathways such as TGF-β. This review systematically summarizes different categories of PTMs, organizes the PTMs involved in various injury stages of IPF, outlines the roles of different cells throughout the process, and analyzes future clinical diagnosis and treatment strategies as well as intervention targets for IPF, providing guiding significance for the systematic intervention of IPF in the future.